Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051909 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT00051909: Completed Phase 2 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
NCT00051909 is a Phase 2 study of Alzheimers Disease that has completed, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051909, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
Conditions Studied
Interventions
- DRUG LY451395
Study Locations (9)
Florida
- - Boca Raton
- - Fort Lauderdale
- - Miami Beach
California
- - Beverly Hills
- - Fresno
Oklahoma
- - Oklahoma City
- - Tulsa
Massachusetts
- - Boston
Texas
- - Wichita Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00051909 record still lists
NCT00051909 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which LY451395 is the first listed.
NCT00051909 lists 9 locations in 5 states (Florida, California, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT00051909 about?
NCT00051909 is a clinical study titled "Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease". Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
What is the current status of trial NCT00051909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2002-11. Estimated completion is 2003-06.
What conditions does trial NCT00051909 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00051909?
The interventions under investigation include: LY451395 (DRUG).
Who is sponsoring clinical trial NCT00051909?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051909 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00051909's enrollment target sits among peer trials
200 60th of 147 higher than 88 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia